On the 28 May 2020, the U.S. Food and Drug Administration (FDA) approved Tauvid—a radioactive tracer—for positron emission tomography (PET) imaging of tau pathology in Alzheimer’s disease (AD) [1]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.